Skip to Main Content
Title
Public policy and pharmaceutical innovation.
First Author
Grabowski, Henry G
Date of Pub
1982 Sep
Pages
75-87
Volume
4
Issue
1
Other Authors
N/A
Abstract
Historically, new drug introductions have played a central role in medical progress and the availability of cost-effective therapies. Nevertheless, public policy toward pharmaceuticals has been characterized in recent times by increasingly stringent regulatory controls, shorter effective patent terms, and increased encouragement of generic product usage. This has had an adverse effect on the incentives and capabilities of firms to undertake new drug research and development activity. The industry has experienced sharply rising research and development costs, declining annual new drug introductions, and fewer independent sources of drug development. This paper considers the effects of government regulatory policies on the pharmaceutical innovation process from several related perspectives. It also examines the merits of current public policy proposals designed to stimulate drug innovation including patent restoration and various regulatory reform measures.
Abstract Continued
N/A
MeSH
Drug Industry : Public Policy : Diffusion of Innovation : Legislation, Drug/trends : Research Support : United States : United States Food and Drug Administration
NTIS Number
PB83-104414